Biological vs Chronological Age: Are Geriatricians Ready for ‘Aging Clocks’? Abstract The concept of biological age versus chronological age represents a fundamental shift in how healthcare providers assess aging and age-related health risks. While chronological age measures the time elapsed since birth, biological
Author: Similoluwa Oluwalana
Bite Therapy: CAR-T vs T-Cell Engagers – Which Saves More B-ALL Patients?
Bite Therapy: CAR-T vs T-Cell Engagers – Which Saves More B-ALL Patients? Introduction Bite therapy and CAR-T cell treatments have revolutionized the management of B-cell acute lymphoblastic leukemia (B-ALL), achieving remarkable remission rates. Second-generation CD19-targeted chimeric antigen receptor T cells achieve dramatic remission
Metformin in 2025: Still the King or Time to Step Aside?
Epigenetics and Brain Plasticity: Can We Rewrite the Neurological Code?
Anemia of Chronic Disease: Unravelling New Pathways Beyond Iron
Anemia of Chronic Disease: Unravelling New Pathways Beyond Iron Abstract Anemia of chronic disease (ACD) represents the second most common form of anemia worldwide, affecting millions of patients with underlying inflammatory conditions. Traditionally understood as a disorder primarily involving disruption of iron metabolism, recent
Hidden Crisis: Why Sarcopenia Treatment Matters More Than You Think in 2025
Hidden Crisis: Why Sarcopenia Treatment Matters More Than You Think in 2025 Introduction Sarcopenia treatment represents a critical healthcare priority as the prevalence of this age-related muscle wasting condition reaches alarming levels. The economic burden of sarcopenia in the United States was approximately
AI Risk Scores vs HEART Score: Which Better Predicts Chest Pain Outcomes?
Climate Change and Children’s Health: Preparing Pediatricians for New Frontiers
Climate Change and Children’s Health: Preparing Pediatricians for New Frontiers Abstract Climate change poses serious threats to children’s health worldwide. This paper examines how environmental changes affect pediatric health outcomes and explores strategies for preparing healthcare professionals to address these challenges. By
Factor 11a Inhibitors vs DOACs: The New Standard in Anticoagulation Therapy?
Factor 11a Inhibitors vs DOACs: The New Standard in Anticoagulation Therapy? Introduction Venous thromboembolism (VTE) affects nearly 900,000 people annually in the United States, with an estimated 60,000-100,000 individuals dying from related complications. Factor 11a inhibitors represent a promising new frontier in anticoagulation
Controversies in Antiphospholipid Syndrome: DOACs vs. Warfarin
Controversies in Antiphospholipid Syndrome: DOACs vs. Warfarin Check out our extensive video library (see channel for our latest videos) Abstract Antiphospholipid syndrome (APS) represents a complex autoimmune disorder characterized by thrombotic events and pregnancy complications in patients with persistent antiphospholipid antibodies. The traditional anticoagulant
